MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock, net of...
$23,346K
Proceeds from
at-the-market offering, net of...
$3,732K
Net cash provided by
financing activities
$26,699K
Canceled cashflow
$379K
Net increase
(decrease) in cash, cash...
$6,638K
Canceled cashflow
$20,061K
Taxes paid related to
net share...
$379K
Accounts payable and
other accrued...
$4,936K
Refundable research income
tax credits
-$4,525K
Prepaid expenses and
other assets
-$1,201K
Stock-based compensation
$992K
Depreciation and
amortization
$719K
Accrued compensation
and employee...
$630K
Amortization in operating
lease right-of-use...
$158K
Net cash used in
operating activities
-$19,282K
Effect of exchange rate
changes on cash, cash...
-$766K
Net cash used in
investing activities
-$13K
Canceled cashflow
$13,161K
Net loss
-$30,995K
Purchases of property and
equipment
$13K
Accounts receivable
$502K
Deferred revenues
-$497K
Lease liabilities
-$449K
Back
Back
Cash Flow
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)
source: myfinsight.com